(Q34665691)

3 August 2017

1 reference

title

Acute myeloid leukemia: 2014 update on risk-stratification and management (English)

1 reference

3 August 2017

1 reference

acute myeloid leukemia

1 reference

Elihu H Estey

1

1 reference

3 August 2017

language of work or name

1 reference

1 November 2014

1 reference

American Journal of Hematology

3 August 2017

published in

1 reference

3 August 2017

volume

89

1 reference

3 August 2017

issue

11

1 reference

3 August 2017

page(s)

1063-1081

1 reference

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

3 August 2017

cites work

1 reference

Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification

21 January 2018

1 reference

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

21 January 2018

1 reference

Age and acute myeloid leukemia

21 January 2018

1 reference

Relapse and death during first remission in acute myeloid leukemia

21 January 2018

1 reference

Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson

21 January 2018

1 reference

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia

21 January 2018

1 reference

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.

21 January 2018

1 reference

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

21 January 2018

1 reference

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

21 January 2018

1 reference

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

21 January 2018

1 reference

Acute myeloid leukemia: 2013 update on risk-stratification and management

21 January 2018

1 reference

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.

21 January 2018

1 reference

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome

21 January 2018

1 reference

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients

21 January 2018

1 reference

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score

21 January 2018

1 reference

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

21 January 2018

1 reference

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

21 January 2018

1 reference

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

21 January 2018

1 reference

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

21 January 2018

1 reference

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

21 January 2018

1 reference

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

21 January 2018

1 reference

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

21 January 2018

1 reference

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

21 January 2018

1 reference

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial

21 January 2018

1 reference

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

21 January 2018

1 reference

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

21 January 2018

1 reference

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

21 January 2018

1 reference

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

21 January 2018

1 reference

Gemtuzumab ozogamicin: time to resurrect?

21 January 2018

1 reference

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

21 January 2018

1 reference

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

21 January 2018

1 reference

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

21 January 2018

1 reference

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm

21 January 2018

1 reference

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

21 January 2018

1 reference

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

21 January 2018

1 reference

The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond

21 January 2018

1 reference

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

21 January 2018

1 reference

The past and future of CD33 as therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation

21 January 2018

1 reference

Reduced mortality after allogeneic hematopoietic-cell transplantation

21 January 2018

1 reference

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

21 January 2018

1 reference

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission

21 January 2018

1 reference

HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.

21 January 2018

1 reference

21 January 2018

1 reference

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

21 January 2018

1 reference

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

21 January 2018

1 reference

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies

21 January 2018

1 reference

Cytarabine dose for acute myeloid leukemia

21 January 2018

1 reference

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

21 January 2018

1 reference

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23834

1 reference

3 August 2017

1 reference